Chinese Journal of Stroke ›› 2023, Vol. 18 ›› Issue (10): 1095-1100.DOI: 10.3969/j.issn.1673-5765.2023.10.001
Previous Articles Next Articles
ZHENG Huaguang, WANG Yongjun
Received:
2023-10-02
Online:
2023-10-20
Published:
2023-10-20
郑华光,王拥军
通讯作者:
王拥军 yongjunwang@ncrcnd.org.cn
基金资助:
ZHENG Huaguang, WANG Yongjun. Brain Health: Precise Evaluation and Scientific Managment[J]. Chinese Journal of Stroke, 2023, 18(10): 1095-1100.
郑华光, 王拥军. 脑健康:精准评估和科学管理[J]. 中国卒中杂志, 2023, 18(10): 1095-1100.
[1] WANG Y J,PAN Y S,LI H. What is brain health and why is it important?[J/OL]. BMJ,2020,371:m3683[2023-10-01]. https://doi.org/10.1136/bmj.m3683. [2] GORELICK P B,FURIE K L,IADECOLA C,et al. Defining optimal brain health in adults:a presidential advisory from the American Heart Association/American Stroke Association[J/OL]. Stroke,2017,48(10):e284-e303[2023-10-01]. https://doi.org/10.1161/str.0000000000000148. [3] CHEN Y H,DEMNITZ N,YAMAMOTO S,et al. Defining brain health:concept analysis[J/OL]. Int J Geriatr Psychiatry,2021,37(1):5564[2023-10-01]. https://doi.org/10.1002/gps.5564. [4] GBD 2016 Neurology Collaborators. Global,regional,and national burden of neurological disorders,1990-2016:a systematic analysis for the global burden of disease study 2016[J]. Lancet Neurol,2019,18(5):459-480. [5] WANG Y J,LI Z X,GU H Q,et al. China stroke statistics:an update on the 2019 report from the National Center for Healthcare Quality Management in Neurological Diseases,China National Clinical Research Center for Neurological Diseases,the Chinese Stroke Association,National Center for Chronic and Non-communicable Disease Control and Prevention,Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations[J]. Stroke Vasc Neurol,2022,7(5):415-450. [6] JIA L F,DU Y F,CHU L,et al. Prevalence,risk factors,and management of dementia and mild cognitive impairment in adults aged 60 years or older in China:a cross-sectional study[J/OL]. Lancet Public Health,2020,5(12):e661-e671[2023-10-01]. https://doi.org/10.1016/s2468-2667(20)30185-30187. [7] GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050:an analysis for the global burden of disease study 2019[J/OL]. Lancet Public Health,2022,7(2):e105-e125[2023-10-01]. https://doi.org/10.1016/s2468-2667(21)00249-8. [8] MINTUN M A,LO A C,DUGGAN EVANS C,et al. Donanemab in early Alzheimer's disease[J]. N Engl J Med,2021,384(18):1691-1704. [9] SIMS J R,ZIMMER J A,EVANS C D,et al. Donanemab in early symptomatic Alzheimer disease:the TRAILBLAZER-ALZ 2 randomized clinical trial[J]. JAMA,2023,330(6):512-527. [10] van DYCK C H,SABBAGH M,COHEN S,et al. Lecanemab in early Alzheimer's disease[J]. N Engl J Med,2022,388(17):1631-1632. [11] SPERLING R A,DONOHUE M C,RAMAN R,et al. Trial of Solanezumab in preclinical Alzheimer's disease[J]. N Engl J Med,2023,389(12):1096-1107. [12] SCHELTENS P,DE STROOPER B,KIVIPELTO,et al. Alzheimer's disease[J]. Lancet,2021,397(10284):1577-1590. [13] JACK C R. Advances in Alzheimer's disease research over the past two decades[J]. Lancet Neurol,2022,21(10):866-869. [14] FEIGIN V L,ROTH G A,NAGHAVI M,et al. Global burden of stroke and risk factors in 188 countries,during 1990-2013:a systematic analysis for the global burden of disease study 2013[J]. Lancet Neurol,2016,15(9):913-924. [15] LIVINGSTON G,HUNTLEY J,SOMMERLAD A,et al. Dementia prevention,intervention,and care:2020 report of the Lancet Commission[J]. Lancet,2020,396(10248):413-446. [16] SATIZABAL C L,BEISER A S,CHOURAKI V,et al. Incidence of dementia over three decades in the Framingham heart study[J]. N Engl J Med,2016,374(6):523-532. [17] WU Y T,BEISER A S,BRETELER M M B,et al. The changing prevalence and incidence of dementia over time - current evidence[J]. Nat Rev Neurol,2017,13(6):327-339. [18] FRIBERG L,ROSENQVIST M. Less dementia with oral anticoagulation in atrial fibrillation[J]. Eur Heart J,2018,39(6):453-460. [19] SPRINT research group,WRIGHT J T,WILLIAMSON J D,et al. A randomized trial of intensive versus standard blood-pressure control[J]. N Engl J Med,2015,373(22):2103-2116. [20] WILLIAMSON J D,PAJEWSKI N M,AUCHUS A P,et al. Effect of intensive vs standard blood pressure control on probable dementia:a randomized clinical trial[J]. JAMA,2019,321(6):553-561. [21] NGANDU T,LEHTISALO J,SOLOMON A,et al. A 2 year multidomain intervention of diet,exercise,cognitive training,and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people(FINGER):a randomised controlled trial[J]. Lancet,2015,385(9984):2255-2263. [22] LEHTISALO J,RUSANEN M,SOLOMON A,et al. Effect of a multi-domain lifestyle intervention on cardiovascular risk in older people:the FINGER trial[J]. Eur Heart J,2022,43(21):2054-2061. [23] KALARIA R N,MAESTRE G E,ARIZAGA R,et al. Alzheimer's disease and vascular dementia in developing countries:prevalence,management,and risk factors[J]. Lancet Neurol,2008,7(9):812-826. [24] GOODMAN R A,LOCHNER K A,THAMBISETTY M,et al. Prevalence of dementia subtypes in United States medicare fee-for-service beneficiaries,2011-2013[J]. Alzheimers Dement,2017,13(1):28-37. [25] ARVANITAKIS Z,SHAH R C,BENNETT D A,et al. Diagnosis and management of dementia:review[J]. JAMA,2019,322(16):1589-1599. [26] van der FLIER W M,SKOOG L,SCHNEIDER J A,et al. Vascular cognitive impairment[J/OL]. Nat Rev Dis Primers,2018,4:18003[2023-10-01]. https://doi.org/10.1038/nrdp.2018.3. [27] CHEN C L H,RUNDEK T. Vascular Brain Health[J]. Stroke,2021,52(11):3700-3705. [28] GREENBERG S M. Vascular contributions to brain health:cross-cutting themes[J]. Stroke,2022,53(2):391-393. [29] HACHINSKI V,EINHÄUPL K,GANTEN D,et al. Preventing dementia by preventing stroke:the Berlin Manifesto[J]. Alzheimers Dement,2019,15(7):961-984. [30] PANDIAN J D,GALL S L,KATE M P,et al. Prevention of stroke:a global perspective[J]. Lancet,2018,392(10154):1269-1278. [31] OWOLABI M O,THRIFT A G,MAHAL A,et al. Primary stroke prevention worldwide:translating evidence into action[J/OL]. Lancet Public Health,2022,7(1):e74-e85[2023-10-01]. https://doi.org/10.1016/s2468-2667(21)00230-9. [32] SABAYAN B. Primary prevention of ischemic stroke[J]. Semin Neurol,2022,42(5):571-582. [33] MANGIONE C M,BARRY M J. Statin use for the primary prevention of cardiovascular disease in adults:US preventive services task force recommendation statement[J]. JAMA,2022,328(8):746-753. [34] ELLIOTT J,BODINIER B,BOND T A,et al. Predictive accuracy of a polygenic risk score-enhanced prediction model vs a clinical risk score for coronary artery disease[J]. JAMA,2020,323(7):636-645. [35] KHAN S S,POST W S,GUO X Q,et al. Coronary artery calcium score and polygenic risk score for the prediction of coronary heart disease events[J]. JAMA,2023,329(20):1768-1777. [36] CHO L,DAVIS M,ELGENDY I,et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women:JACC state-of-the-art review[J]. J Am Coll Cardiol,2020,75(20):2602-2618. [37] BERSANO A,KRAEMER M,BURLINA A,et al. Heritable and non-heritable uncommon causes of stroke[J]. J Neurol,2021,268(8):2780-2807. [38] BOS D,ARSHI B,van den BOUWHUIJSEN Q J A,et al. Atherosclerotic carotid plaque composition and incident stroke and coronary events[J]. J Am Coll Cardiol,2021,77(11):1426-1435. [39] SABA L,SAAM T,JÄGER H R,et al. Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications[J]. Lancet Neurol,2019,18(6):559-572. [40] KAMTCHUM-TATUENE J,SABA L,HELDNER M R,et al. Interleukin-6 predicts carotid plaque severity,vulnerability,and progression[J/OL]. Circ Res,2022,131(2):e22-e33[2023-10-01]. https://doi.org/10.1161/circresaha.122.320877. [41] ALTOMARE D,MOLINUEVO J L,RITCHIE C,et al. Brain health services:organization,structure,and challenges for implementation. a user manual for brain health services-part 1 of 6[J/OL]. Alzheimers Res Ther,2021,13(1):168[2023-10-01]. https://doi.org/10.1186/s13195-021-00827-2/. [42] FRISONI G B,ALTOMARE D,RIBALDI F,et al. Dementia prevention in memory clinics:recommendations from the European task force for brain health services[J/OL]. Lancet Reg Health Eur,2023,26:100576[2023-10-01]. https://doi.org/10.1016/j.lanepe.2022.100576. [43] JESSEN F,AMARIGLIO R E,BUCKLEY R F,et al. The characterisation of subjective cognitive decline[J]. Lancet Neurol,2020,19(3):271-278. [44] HALLETT M,AYBEK S,DWORETZKY B A,et al. Functional neurological disorder:new subtypes and shared mechanisms[J]. Lancet Neurol,2022,21(6):537-550. [45] HAMPEL H,CUMMINGS J,BLENNOW K,et al. Developing the ATX(N)classification for use across the Alzheimer disease continuum[J]. Nat Rev Neurol,2021,17(9):580-589. [46] MATTSSON-CARLGREN N,SALVADÓ G,ASHTON N J,et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers[J]. JAMA Neurol,2023,80(4):360-369. [47] TEUNISSEN C E,VERBERK I M W,THIJSSEN E H,et al. Blood-based biomarkers for Alzheimer's disease:towards clinical implementation[J]. Lancet Neurol,2022,21(1):66-77. [48] JANSEN W J,JANSSEN O,TIJMS B M,et al. Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum[J]. JAMA Neurol,2022,79(3):228-243. [49] GRAFF-RADFORD J,YONG K X X,APOSTOLOVA L G,et al. New insights into atypical Alzheimer's disease in the era of biomarkers[J]. Lancet Neurol,2021,20(3):222-234. [50] CHEN L H,DHANA K,HUANG Y,et al. Association of the mediterranean dietary approaches to stop hypertension intervention for neurodegenerative delay(MIND)diet with the risk of dementia[J]. JAMA Psychiatry,2023,80(6):630-638. [51] SOININEN H,SOLOMON A,VISSER P J,et al. 36-month lipididiet multinutrient clinical trial in prodromal Alzheimer's disease[J]. Alzheimers Dement,2021,17(1):29-40. [52] BARNES L L,DHANA K,LIU X R,et al. Trial of the MIND diet for prevention of cognitive decline in older persons[J]. N Engl J Med,2023,389(7):602-611. [53] RAICHLEN D A,ASLAN D H,SAYRE M K,et al. Sedentary behavior and incident dementia among older adults[J]. JAMA,2023,330(10):934-940. [54] LAUTENSCHLAGER N T,COX K L,FLICKER L,et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease:a randomized trial[J]. JAMA,2008,300(9): 1027-1037. [55] SINK K M,ESPELAND M A,CASTRO C M,et al. Effect of a 24-month physical activity intervention vs health education on cognitive outcomes in sedentary older adults:the LIFE randomized trial[J]. JAMA,2015,314(8):781-790. [56] CHÉTELAT G,LUTZ A,KLIMECKI O,et al. Effect of an 18-month meditation training on regional brain volume and perfusion in older adults:the age-well randomized clinical trial[J]. JAMA Neurol,2022,79(11):1165-1174. [57] LENZE E J,VOEGTLE M,MILLER J P,et al. Effects of mindfulness training and exercise on cognitive function in older adults:a randomized clinical trial[J]. JAMA,2022,328(22):2218-2229. [58] LLOYD-JONES D M,ALLEN N B,Anderson c a m,et al. Life's essential 8:updating and enhancing the American Heart Association's Construct of Cardiovascular Health:a presidential advisory from the American Heart Association[J/OL]. Circulation,2022,146(5):e18-e43[2023-10-01]. https://doi.org/10.1161/cir.0000000000001078. [59] WANG X,MA H,LI X,et al. Association of cardiovascular health with life expectancy free of cardiovascular disease,diabetes,cancer,and dementia in UK adults[J]. JAMA Intern Med,2023,183(4):340-349. [60] Van CHARANTE E P M,RICHARD E,EURELINGS L S,et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia(preDIVA):a cluster-randomised controlled trial[J]. Lancet,2016,388(10046):797-805. [61] ANDRIEU S,GUYONNET S,COLEY N,et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints(MAPT):a randomised,placebo-controlled trial[J]. Lancet Neurol,2017,16(5):377-389. [62] OBERLIN L E,JAYWANT A,WOLFF A,et al. Strategies to promote cognitive health in aging:recent evidence and innovations[J]. Curr Psychiatry Rep,2022,24(9):441-450. [63] COLZATO L S,HOMMEL B,BESTE C,et al. The downsides of cognitive enhancement[J]. Neuroscientist,2021,27(4):322-330. [64] DAWSON W D,BOBROW K,IBANEZ A,et al. The necessity of diplomacy in brain health[J]. Lancet Neurol,2020,19(12):972-974. |
[1] |
LIU Fei, WANG Xiaoyan, LIANG Yanchao, LI Shuang, SHAN Kai.
A Study on the Evaluation of Hospital Neurological Specialty Capacity Based on TOPSIS Method and Boston Matrix [J]. Chinese Journal of Stroke, 2024, 19(8): 880-887. |
[2] | QIAN Jinping, WU Dan, GUO Xiaoling. Construction of Core Competency Evaluation Index System for Brain and Heart Health Managers [J]. Chinese Journal of Stroke, 2024, 19(2): 181-189. |
[3] | YANG Caixia, YI Haibo, QI Lu, HU Qiongdan, SUN Ye, LI Dongmei, MA Keke, LI Yapeng, XU Yuming, GUO Yuanli. Construction of Quality Evaluation Index System for Brain and Heart Health Managers Based on the Structure-Process-Outcome Three-Dimensional Quality Model [J]. Chinese Journal of Stroke, 2024, 19(11): 1359-1367. |
[4] | WANG Fang-Xu, TAO Li-Bo. Review on Health Economic Evaluation Models of Ischemic Stroke [J]. Chinese Journal of Stroke, 2021, 16(03): 265-271. |
[5] | ZHOU Lu, LIU Gao, HE Yi-Xian, CAI En-Li. Quality Evaluation of Clinical Practice Guidelines for Management of Acute Ischemic Stroke-Associated Pneumonia: A Study Based on AGREE II [J]. Chinese Journal of Stroke, 2021, 16(01): 51-57. |
[6] | YE Shan,SONG Hong-Song, ZHAO Hai-Yan, FAN Dong-Sheng, LI Xiao-Gang. Milestones Evaluation Feedback Model Based on Core Competency in Neurology Resident Training [J]. Chinese Journal of Stroke, 2020, 15(10): 1134-1137. |
[7] | ZHAO Ting-Ting, LI Guo-Zhong, ZHONG Di, CHEN Hong-Ping. Progress of Imaging Evaluation of Cerebral Collateral Circulation [J]. Chinese Journal of Stroke, 2018, 13(05): 516-520. |
[8] | QIAO Han-Zi, LIAO Wen-Jing, NI Xiao-Jia, ZHU Qing-Bin, LIN Hao, LUO Xu-Fei, CHEN Yao-Long, CAI Ye-Feng. Systematic Evaluation of Chinese Guidelines on Pharmacotherapy for Ischemic Stroke [J]. Chinese Journal of Stroke, 2018, 13(04): 327-332. |
[9] | YU Jia-Li, YIN Shi-Min, LU Yan, XU Fang, WANG Qiu-Jia, WANG Lei. The Intervention Effect Study on Computer Simulated Training in Vascular Cognitive Impairment [J]. Chinese Journal of Stroke, 2017, 12(10): 921-928. |
[10] | DENG Yi-Ming, HUO Xiao-Chuan, GAO Feng, et al.. The Evaluation of Clinical Effect and Efficiency of Endovascular Treatment for Acute Ischemic Stroke Treatment [J]. Chinese Journal of Stroke, 2016, 11(10): 829-835. |
[11] | ZHANG Xu, LIANG Jun, SANG Ben. Efficacy Evaluation of Decompressive Hemicraniectomy Surgery in Large Cerebral Infarction [J]. Chinese Journal of Stroke, 2016, 11(10): 842-846. |
[12] | LIANG Zhi-Feng, HONG Ye, ZHANG Xiao-Ying, et al.. The Correlation between Electroencephalography Mental Evaluation and Anxiety and Depression Emotional Evaluation of Rehabilitation Patients with Brain Injury [J]. Chinese Journal of Stroke, 2016, 11(09): 733-737. |
[13] | SANG Wen-Wen, HONG Yuan, YANG Xu. Bedside Evaluation of Vertigo Patients [J]. Chinese Journal of Stroke, 2015, 10(05): 414-422. |
[14] | ZHANG Lin, ZHAO Ling-Xiu, REN Pei-Juan, CHEN Lu, XU Bei-Bei, WANG Yi-Long.. Development of Cerebrovascular Disease Subject Provides Insight into the Role of Discipline Evaluation for Hospital [J]. Chinese Journal of Stroke, 2014, 9(04): 358-362. |
[15] | LIU Gai-Fen;LI Xian;WANG Yi-Long;et al. Evaluation of Medical Service Performance in Cerebrovascular Disease Inpatients in Beijing [J]. , 2012, 7(08): 606-610. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||